p.140 抽出テキスト
209. Polonsky TS, Tian L, Zhang D, et al. Associations of Weight Change With Changes in Calf Muscle Characteristics and Functional Decline in Peripheral Artery Disease. J Am Heart Assoc 2019; 8: e010890. PMID: 31257970 210. Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. Vasc Med 2020; 25: 106-117. PMID: 31964311 211. Sofat S, Chen X, Chowdhury MM, et al. Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg 2021; 62: 450-461. PMID: 34389230 212. Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018; 6: 934- 943. PMID: 30396865 213. Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018; 137: 338-350. PMID: 29133605 214. Emanuelsson F, Nordestgaard BG, Tybjærg-Hansen A, et al. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol 2019; 74: 1465-1476. PMID: 31514949 215. Westin GG, Armstrong EJ, Bang H, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014; 63: 682-690. PMID: 24315911 216. Kumbhani DJ, Steg PG, Cannon CP, et al. REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35: 2864-2872. PMID: 24585266 217. Hira RS, Cowart JB, Akeroyd JM, et al. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol 2016; 118: 1144-1149. PMID: 27553104 218. Colantonio LD, Hubbard D, Monda KL, et al. Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. J Am Coll Cardiol 2020; 76: 251-264. PMID: 32674789 219. Teramoto T, Uno K, Miyoshi I, et al. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis 2016; 251: 248-254. PMID: 27419905 220. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 69: 1465-1508. PMID: 27851991 221. Abola MTB, Golledge J, Miyata T, et al. Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. J Atheroscler Thromb 2020; 27: 809-907. PMID: 32624554 222. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41: 111-188. PMID: 31504418 223. 日本動脈硬化学会.動脈硬化性疾患予防のための脂質異常症診療ガイド 2018年版.2018. 224. 日本動脈硬化学会.動脈硬化性疾患予防ガイドライン 2017年版. 2017 225. Ishikawa Y, Yokoyama M, Saito Y, et al. JELIS Investigators. Pre- ventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease: Subanalysis of the JELIS trial . Circ J 2010; 74: 1451-1457. PMID: 20484828 226. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325: 1139. PMID: 12433762 227. Rajamani K, Colman PG, Li LP, et al. FIELD study investigators. Ef- fect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788. PMID: 19465233 228. Tsuchida H, Shigematsu H, Ishimaru S, et al. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiol 2006; 25: 287-292. PMID: 16878078 229. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393. PMID: 12556541 230. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591. PMID: 18256393 231. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDI- TION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156- 167. PMID: 21705063 232. Ueki K, Sasako T, Okazaki Y, et al. J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 951-964. PMID: 29079252 233. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431. PMID: 15381515 234. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169. PMID: 21791495 235. Hasan R, Firwana B, Elraiyah T, et al. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. J Vasc Surg 2016; 63 Suppl: 22S-28S. PMID: 26804364 236. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589. PMID: 18784090 237. Hayward RA, Reaven PD, Wiitala WL, et al. VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197-2206. PMID: 26039600 238. Orchard TJ, Nathan DM, et al. Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015; 313: 45-53. PMID: 25562265 239. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. PMID: 9742976 240. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322. PMID: 27295427 241. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844. PMID: 27633186 242. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130. PMID: 31189511 243. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-2257. PMID: 26630143 244. Holman RR, Bethel MA, Mentz RJ, et al. EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228-1239. PMID: 28910237 245. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128. PMID: 26378978 246. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657. PMID: 28605608 247. Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347-357. PMID: 30415602 248. Cardoso CRL, Melo JV, Santos TRM, et al. Traditional and non-traditional risk factors for peripheral artery disease development/progression in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol 2021; 20: 54. PMID: 33639945 249. Maeda Y, Inoguchi T, Etoh E, et al. Brachial-ankle pulse wave ve-